Partnership Including an Out-Licensing Agreement for an Oncology Project
First written in FY2016-Q3. 12 of 18 entries say "Restated". Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024AdvancedAnnual report
「For this antibody drug candidate, Mitsubishi Tanabe Pharma Corporation submitted the initial clinical trial notification to the Pharmaceuticals and Medical Devices Agency (PMDA), and the 30-day review was completed. As a result, in June 2024 we received the milestone payment stipulated under the licensing agreement.」
For the exclusive licensing agreement with Mitsubishi Tanabe Pharma, the achievement of a development milestone, namely the submission of the initial clinical trial notification and completion of the PMDA review, and receipt of milestone revenue have been reported. - FY2021-Q3RestatedAnnual report
「Based on these results, we and Mitsubishi Tanabe Pharma Corporation entered into an exclusive licensing agreement in January 2021. Going forward, we will receive development milestone payments according to the stage of development. If this antibody drug is launched into the ¥5 trillion antibody drug market for autoimmune diseases, we will also receive royalties based on worldwide sales and sales milestone payments.」
The concluded status of the licensing agreement has been reconfirmed, and the potential for future development milestone payments, sales milestone payments and royalties has been described. - FY2021-Q2AchievedAnnual report
「Based on these results, we and Mitsubishi Tanabe Pharma Corporation decided to enter into an exclusive licensing agreement and advance the program to the development stage as an antibody drug. Upon execution of the agreement, we recorded an upfront payment of ¥320 million.」
For the project targeting a licensing agreement with a pharmaceutical company, an exclusive licensing agreement was actually concluded with Mitsubishi Tanabe Pharma, and an upfront payment of ¥320 million was recorded. - FY2021-Q1AdvancedAnnual report
「For the “autoimmune disease project,” we entered into a 2-year joint research agreement with Mitsubishi Tanabe Pharma Corporation in October 2018 concerning antibody drugs and received a total of ¥250 million in consideration over the 2-year period. As a result, we achieved the joint research objectives and made steady progress toward an exclusive licensing agreement with the company. If the agreement is concluded, our revenue structure is expected to change significantly as we receive an upfront payment, development milestone payments at each stage of development, and royalties based on drug sales.」
The achievement of the joint research objectives with Mitsubishi Tanabe Pharma is reported, along with receipt of total consideration of ¥250 million for the joint research, followed by progress to the stage of pursuing an exclusive licensing agreement. The conclusion of the agreement itself has not yet been reported. - FY2020-Q3RestatedAnnual report
「Good results have been obtained in the evaluation studies, and steady progress has been made toward a licensing agreement during the current fiscal year, increasing the likelihood that this will become a long-term source of revenue.」
For the autoimmune disease project, progress toward a licensing agreement during the current fiscal year continues to be reported based on favorable evaluation results. - FY2020-Q2AdvancedAnnual report
「Good results have been obtained in the evaluation studies, and steady progress has been made toward a licensing agreement during the current fiscal year, increasing the likelihood that this will become a source of revenue.」
Good evaluation results were obtained in the joint research on an autoimmune disease antibody drug with Mitsubishi Tanabe Pharma, and progress toward a licensing agreement during the current fiscal year has been explicitly reported. - FY2020-Q1RestatedAnnual report
「As a drug candidate for osteogenesis imperfecta, we will investigate the mechanism of action of “ReproTite®” and evaluate its efficacy in animal models while continuing partnership negotiations with pharmaceutical companies.」
We have reconfirmed our policy of continuing partnership negotiations with pharmaceutical companies while advancing research and efficacy evaluations of drug candidates. - FY2019RestatedAnnual report
「For each of the ongoing “autoimmune disease project,” “malignant tumor project” and “bone formation project,” we will conduct negotiations and research sequentially, aiming for the early conclusion of licensing agreements with pharmaceutical companies and the prompt advancement of preclinical research.」
For the 3 drug discovery projects, we continue to pursue the advancement of licensing agreements with pharmaceutical companies and preclinical research. No agreement has been reported as concluded. - FY2019-Q3RestatedAnnual report
「We will continue to pursue joint research while continuing partnership negotiations with pharmaceutical companies.」
For the drug discovery projects, we are continuing joint research and partnership negotiations with pharmaceutical companies. No new licensing-out agreement has been reported as concluded. - FY2019-Q2RestatedAnnual report
「We will continue to pursue joint research while continuing partnership negotiations with pharmaceutical companies.」
For the malignant tumor project and other projects, we are continuing joint research and partnership negotiations with pharmaceutical companies. No new licensing-out agreement has been reported as concluded. - FY2019-Q1RestatedAnnual report
「As a drug candidate for osteogenesis imperfecta, we will investigate the mechanism of action of “ReproTite” and evaluate its efficacy in animal models while pursuing partnership negotiations with pharmaceutical companies.」
For drug discovery projects, including the bone formation project, we are continuing research and partnership negotiations with pharmaceutical companies. No new licensing-out agreement has been reported as concluded. - FY2018-Q3RestatedAnnual report
「In the “malignant tumor project,” as part of our joint research with the National Cancer Center, we are conducting sequential expression analyses of FSTL1 in various human malignant tumor tissues held in large quantities by the Center. Across all projects, we are pursuing joint research with public research institutions while continuing partnership negotiations with multiple domestic and overseas pharmaceutical companies.」
For the drug discovery projects, we are continuing joint research and partnership negotiations with multiple domestic and overseas pharmaceutical companies. No new licensing-out agreement has been reported as concluded. - FY2018-Q2RestatedAnnual report
「For all projects, we are pursuing joint research with public research institutions while continuing partnership negotiations with multiple domestic and overseas pharmaceutical companies.」
For the drug discovery projects, we are continuing joint research and partnership negotiations with multiple pharmaceutical companies. No new licensing-out agreement has been reported as concluded. - FY2018-Q1RestatedAnnual report
「Across all projects, we are pursuing joint research with public research institutions while continuing partnership negotiations with multiple domestic and overseas pharmaceutical companies.」
For the drug discovery projects, we are continuing joint research with public research institutions and partnership negotiations with multiple domestic and overseas pharmaceutical companies. No agreement has been reported as concluded. - FY2017-Q3RestatedAnnual report
「For these 3 projects, we are pursuing joint research with public research institutions, including the National Cancer Center, while continuing partnership negotiations with multiple domestic and overseas pharmaceutical companies.」
Partnership negotiations with pharmaceutical companies are continuing for drug discovery projects, including the malignant tumor project. No new licensing-out agreement has been reported as concluded. - FY2017-Q2RestatedAnnual report
「In particular, for the “malignant tumor project,” we are pursuing joint research with the National Cancer Center while continuing partnership negotiations with multiple domestic and overseas pharmaceutical companies.」
Negotiations are continuing with multiple domestic and overseas pharmaceutical companies regarding partnerships, including licensing-out agreements. No new agreement has been reported as concluded. - FY2017-Q1AdvancedAnnual report
「For the “malignant tumor project,” we have entered into MTAs (agreements for the supply of test drugs to confirm efficacy) with multiple pharmaceutical companies and are continuing partnership negotiations.」
Progress has been made through the execution of MTAs with multiple pharmaceutical companies, and partnership negotiations are continuing. No licensing-out agreement itself has been reported as concluded. - FY2016-Q3First statedAnnual report
「We are currently discussing partnerships, including licensing-out agreements, with pharmaceutical companies in order of completion of efficacy confirmation and aim to conclude an agreement during the current fiscal year.」
We are advancing evaluations with multiple pharmaceutical companies, discussing partnerships including licensing out after efficacy has been confirmed, and targeting the conclusion of an agreement during the current fiscal year.